Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Trials

Potential treatments for macular degeneration must successfully complete human clinical trials before seeking approval by the U.S. Food and Drug Administration.

Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.

We are currently conducting a Phase 2a study of AVA-101 in wet AMD. Learn More.


Join our mailing list and receive updated information as it becomes available:

Avalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference

November 13, 2014

MENLO PARK, CA – November 13, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Linda C. Bain, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference on Thursday, November 20, 2014 at 8:40 am GMT in London, England.

Read More

Read All Avalanche News